marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-14-2024
Verrica Pharmaceuticals Balance Sheet 2011-2024 | VRCA
Annual Balance Sheet Verrica Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-15.5 M | 59.9 M | -9.05 M | -10.3 M | -8.66 M | -527 K | - | - | - | - | - | ||
Long Term Debt |
42.9 M | - | 16 K | 35.3 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
324 K | 297 K | 245 K | 198 K | 130 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.69 M | 58 K | - | - | 2.79 M | - | - | - | - | - |
Total Current Liabilities |
17 M | 3.46 M | 46.1 M | 39.5 M | 3.35 M | 2.48 M | - | - | - | - | - | - | - |
Total Liabilities |
61.8 M | 4.69 M | 47.5 M | 41.2 M | 3.41 M | 2.48 M | 616 K | 3.21 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | 500 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-230 M | -163 M | -139 M | -104 M | -61.2 M | -33.1 M | -12.4 M | -2.68 M | - | - | - | - | - |
Total Assets |
81.6 M | 44.7 M | 80.1 M | 74.2 M | 68.4 M | 91.9 M | 9.08 M | 544 K | - | - | - | - | - |
Cash and Cash Equivalents |
69.5 M | 34.3 M | 15.8 M | 10.7 M | 9.24 M | 10.3 M | 8.66 M | - | - | - | - | - | - |
Book Value |
19.8 M | 40 M | 32.6 M | 33 M | 65 M | 89.4 M | 8.47 M | -2.66 M | - | - | - | - | - |
Total Shareholders Equity |
19.8 M | 40 M | 32.6 M | 33 M | 65 M | 89.4 M | -7.04 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Verrica Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
42.8 M | 42.8 M | 42.9 M | 42.4 M | 1.07 M | 1.15 M | 1.23 M | - | 13 K | 15 K | 16 K | 18 K | 19 K | 1.63 M | 1.69 M | 1.69 M | 1.69 M | 34.4 M | 58 K | 58 K | 58 K | 58 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
65.3 M | 64.8 M | 61.8 M | 54.8 M | 6.8 M | 3.79 M | 4.69 M | 4.38 M | 47.1 M | 46.2 M | 47.5 M | 47.9 M | 46.9 M | 46.3 M | 41.2 M | 41.2 M | 41.2 M | 41.2 M | 3.41 M | 3.41 M | 3.41 M | 3.41 M | 2.48 M | 2.48 M | 2.48 M | 2.48 M | 616 K | 616 K | 616 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 500 K | 500 K | 500 K | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-268 M | -251 M | -230 M | -206 M | -181 M | -170 M | -163 M | -158 M | -158 M | -147 M | -139 M | -129 M | -117 M | -105 M | -104 M | -104 M | -104 M | -104 M | -61.2 M | -61.2 M | -61.2 M | -61.2 M | -33.1 M | -33.1 M | -33.1 M | -33.1 M | -12.4 M | -12.4 M | -12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
52 M | 66.3 M | 81.6 M | 97.1 M | 62.2 M | 68.6 M | 44.7 M | 49.1 M | 63.4 M | 71.6 M | 80.1 M | 88.8 M | 99 M | 108 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 68.4 M | 68.4 M | 68.4 M | 68.4 M | 91.9 M | 91.9 M | 91.9 M | 91.9 M | 9.08 M | 9.08 M | 9.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
31.9 M | 48.9 M | 69.5 M | 84.3 M | 55.1 M | 60 M | 34.3 M | 32.5 M | 45.4 M | 50.4 M | 15.8 M | 20.4 M | 24.7 M | 44.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 9.24 M | 9.24 M | 9.24 M | 9.24 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 8.66 M | 8.66 M | 8.66 M | - | 527 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-13.3 M | 1.51 M | 19.8 M | 42.3 M | 55.4 M | 64.8 M | 40 M | 44.8 M | 16.3 M | 25.4 M | 32.6 M | 40.9 M | 52.2 M | 61.8 M | 33 M | 33 M | 33 M | 33 M | 65 M | 65 M | 65 M | 65 M | 89.4 M | 89.4 M | 89.4 M | 89.4 M | 8.47 M | 8.47 M | 8.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-13.3 M | 1.51 M | 19.8 M | 42.3 M | 55.4 M | 64.8 M | 40 M | 44.8 M | 16.3 M | 25.4 M | 32.6 M | 40.9 M | 52.2 M | 61.8 M | 33 M | 33 M | 33 M | 33 M | 65 M | 65 M | 65 M | 65 M | 89.4 M | 89.4 M | 89.4 M | 89.4 M | -7.04 M | -7.04 M | -7.04 M | - | -2.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency